Author

M. Zethoven

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Approach:statistical model· 2 Research Focus:cell-cell communication· 1 Approach:deep learning· 1

Frequent Co-Authors

G. Mir Arnau· 2 shared I. Todorovski· 2 shared R. W. Johnstone· 2 shared S. J. Vervoort· 2 shared A. M. N. Silva· 1 shared A. T. Papenfuss· 1 shared A. Wei· 1 shared B. Feran· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Mir Arnau

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

RNA decay defines the therapeutic response to transcriptional perturbation in leukaemia

I. Todorovski, B. Feran, Z. Fan, S. Gadipally, D. Yoannidis, I. Y. Kong, S. Bjelosevic, M. Zethoven, E. D. Hawkins, K. J. Simpson, G. Mir Arnau, A. T. Papenfuss, R. W. Johnstone, S. J. Vervoort

The paper shows that mRNA decay rates determine the effectiveness of transcriptional inhibitors in leukemia, with short-lived mRNAs being more responsive and long-lived ones being modulated by RNA-binding proteins.

bioRxiv · Apr 6, 2022 · PreprintCancer Biology

Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications

M. Lopes, T. Duarte, M. J. Teles, L. Mosteo, S. Chacim, E. Aguiar, J. Pereira-Reis, M. Oliveira, A. M. N. Silva, N. Goncalves, G. Martins, I. Kong, M. Zethoven, S. Vervoort, S. Martins, , D. Duarte

The paper investigates iron metabolism in AML, finding that AML causes iron redistribution through erythroblast loss, leading to high TSAT and improved survival.

bioRxiv · Oct 26, 2020Cancer Biology

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit

J. Salmon, I. Todorovski, S. J. Vervoort, K. L. Stanley, C. J. Kearney, L. Martelotto, F. Rossello, T. Semple, G. Mir Arnau, M. Zethoven, M. Bots, E. Vidacs, K. McArthur, E. Gressier, N. De Weerd, , R. W. Johnstone

The paper shows that inhibiting HDACs in AML promotes type I IFN production by pDCs, enhancing anti-tumor immunity and therapeutic benefit.

bioRxiv · Aug 23, 2020 · PreprintCancer Biology